Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Prognostic Characterization of Advanced Mastocytosis Patients Treated with Midostaurin According to Diagnosis and Mutation-Adjusted Risk Score: A Nation-Wide Ceremast Study of 170 Patients

Mael Heiblig, Clement Gourguechon, Philippe Guilpain, Cristina Bulai Livideanu, Stéphane Barete, Julie Agopian, Fabienne Brenet, Patrice Dubreuil, Richard Lemal, Olivier Tournilhac, Louis Terriou, David Launay, Laurence Bouillet, Gandhi Laurent Damaj, Thomas Ballul, Céline Greco, Laura Polivka, Laurent Frenzel, Cecile Meni, Hassiba Bouktit, Caroline Gaudy-Marqueste, Marie Gousseff, Edwige Le Mouel, Antoine Neel, Dana Ranta, Roland Jaussaud, Thierry Jo Molina, Julie Bruneau, Ludovic Lhermitte, Marie Temple, Olivier Kosmider, Rose-Marie Javier, Fabien Pelletier, Florence Castelain, Frédérique Retornaz, Quentin Cabrera, Patricia Zunic, Marie-Pierre Gourin, Ewa Wierzbicka-Hainaut, Jean-Francois Viallard, Christian Lavigne, Cyrille Hoarau, Isabelle Durieu, Sophie Dimicoli-Salazar, Jose-Miguel Torregrosa-Diaz, Angele Soria, Michel Arock, Christine Bodemer, Olivier Lortholary, Olivier Hermine, Julien Rossignol

Blood (2023) 142 (Supplement 1): 1837.

https://doi.org/10.1182/blood-2023-185890

Published: 2023

Journal Articles

Azacitidine for Patients with Vexas Syndrome: Data from the French Vexas Registry

Thibault Comont, Olivier Kosmider, Mael Heiblig, Benjamin Terrier, Didier Bouscary, Guillaume Le Guenno, Roderau Outh, Maxime Samson, Achille Aouba, Estibaliz Lazarro, Odile Rauzy, Lucie Rigolot, Pierre Peterlin, Alexandre Maria, Edouard Flammarion, Alice Garnier, Benoit De Renzis, Shanti Natarajan, Benjamin Carpentier, Marielle Roux-Sauvat, Jose Torregrosa, Fabienne Closs-Prophette, Julien Rossignol, Nicolas Schleinitz, Celine Dieval, Jonahan Broner, Marie-Pierre Gourin, Gaetan Sauvetre, Benoit Faucher, Julien Vinit, Sylvie Grosleron, Alexis Mathian, Louis Terriou, Cyrille Coustal, Philippe Guilpain, Paola Marianetti-Guingel, Holy Bezanahary, Norbert Vey, Bilal Mohty, Thomas Moulinet, Vincent Grobost, Sophie Dimicoli, Benoit Suzon, Antoinette Perlat, Pierre Hirsh, Lise Larcher, Lin Pierre Zhao, Sophie Georgin-Lavialle, Arsene Mekinian, Pierre Fenaux, Vincent Jachiet, French VEXAS study group, Minhemon French Network of immune disorders associated with hemopathies, GFM Groupe Francophone des Myélodysplasies

Blood (2023) 142 (Supplement 1): 4604.

https://doi.org/10.1182/blood-2023-178125

Published: 2023

Journal Articles

FLT3 Ligand Kinetic Profile Predicts Response to Treatment and Event-Free Survival (EFS) in Adults with High-Risk MDS/CMML Receiving CPX-351: A GFM Study

Pierre Peterlin, Joëlle Gaschet, Pascal Turlure, Marie-Pierre Gourin, Pierre-Yves Dumas, Sylvain Thepot, Ana Berceanu, Sophie Park, Marie Anne Hospital, Thomas Cluzeau, Jose-Miguel Torregrosa-Diaz, Louis Drevon, Rosa Sapena, Fatiha Chermat, Sophie Dimicoli-Salazar, Maxime Jullien, Pierre Fenaux, Patrice Chevallier

Blood (2023) 142 (Supplement 1): 6469.

https://doi.org/10.1182/blood-2023-173741

Published: 2023

Journal Articles

Therapy Related Myeloid Neoplasms Following PARP Inhibitors : Real-Life Experience

Blood (2022) 140 (Supplement 1): 12335–12338.

https://doi.org/10.1182/blood-2022-163478

Published: 2022

Journal Articles

Molecular Response Analysis By High Throughput Sequencing in Higher Risk Myelodysplastic Syndrome (HR-MDS) Treated Intensively with CPX-351

Blood (2022) 140 (Supplement 1): 9821–9823.

https://doi.org/10.1182/blood-2022-162278

Published: 2022

Journal Articles

Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group

Blood (2021) 138 (Supplement 1): 62.

https://doi.org/10.1182/blood-2021-146932

Published: 2021

Journal Articles

A Phase II Study of the Efficacy and Tolerance of Azacytidine (AZA) in Steroid Dependent/Refractory Systemic Autoimmune and Inflammatory Disorders (SAID) Associated with MDS or CMML (GFM- AZA-SAID -trial)

Blood (2021) 138 (Supplement 1): 3697.

https://doi.org/10.1182/blood-2021-150904

Published: 2021

Journal Articles

CPX 351 As First Line Treatment in Higher Risk MDS. a Phase II Trial By the GFM

Pierre Peterlin, Pascal Turlure, Patrice Chevallier, Marie-Pierre Gourin, Pierre-Yves Dumas, Sylvain Thepot, Anna Berceanu, Sophie Park, Marie Anne Hospital, Thomas Cluzeau, Jose Miguel Torregrosa Diaz, Louis Devron, Sylvie Chevret, Marie C Bene, Yannick Le Bris, Rosa Sapena, Fatiha Chermat, Sophie Dimicoli-Salazar, Pierre Fenaux

Blood (2021) 138 (Supplement 1): 243.

https://doi.org/10.1182/blood-2021-145123

Published: 2021

Journal Articles

A Molecular-Based Response Prediction Model to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome and Severe Thrombocytopenia

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-139291

Published: 2020

Journal Articles

Biomarkers of Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - Results of the Europe Trial By the Emsco Network

Blood (2019) 134 (Supplement_1): 2998.

https://doi.org/10.1182/blood-2019-129047

Published: 2019

Journal Articles

French National Retrospective Cohort of Hairy-Cell Leukemias: Risk of Second Malignancies after 10 Years of Follow-up

Blood (2019) 134 (Supplement_1): 1537.

https://doi.org/10.1182/blood-2019-127560

Published: 2019

Journal Articles

Results of a Phase II Study of Guadecitabine (SGI-110) in Higher Risk MDS, CMML or Low Blast Count AML Patients Refractory to or Relapsing after Azacitidine (AZA) Treatment

Blood (2016) 128 (22): 347.

https://doi.org/10.1182/blood.V128.22.347.347

Published: 2016

Journal Articles

Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup

Blood (2014) 124 (8): 1312–1319.

https://doi.org/10.1182/blood-2014-01-549212

Published: 2014

Journal Articles

The Revised IPSS (IPSS-R) Predicts Response To Erythropoietic Stimulating agents (ESA) In Pts With Classical IPSS Low Or Intermediate-1 (int 1)- MDS: A Joint Retrospective Study Of The GFM, Düsseldorf Registry and Fism

Blood (2013) 122 (21): 2761.

https://doi.org/10.1182/blood.V122.21.2761.2761

Published: 2013

Journal Articles

Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?

Blood (2013) 122 (13): 2286–2288.

https://doi.org/10.1182/blood-2013-07-512442

Published: 2013

Journal Articles

FDG-PET/CT Metabolic Tumor Volume: A New Prognostic Marker in Hodgkin Lymphoma?

Marine Boulesteix, Mohamed Touati, Julie Abraham, Sandrine Verbeke, Assmae El Badaoui, Marie Pierre Gourin, Agnes Olivrie, Manuela Delage Corre, Benoit Marin, Arnaud Jaccard, Dominique Bordessoule, MD, PhD, Jacques Monteil

Blood (2012) 120 (21): 3632.

https://doi.org/10.1182/blood.V120.21.3632.3632

Published: 2012

Journal Articles

CD68+ Tumor-Associated Macrophages Predict Unfavorable Treatment Outcomes in Classic Hodgkin's Lymphoma in Correlation with Early FDG-PET Assessment Results

Mohamed Touati, Manuela Delage-Corre, Jacques Monteil, Agnes Olivrie-Gamaury, Stephane Moreau, Liliane Remenieras, Marie-Pierre Gourin, Julie Abraham, Nataliya Dmytruk, Arnaud Jaccard, Dominique Bordessoule

Blood (2011) 118 (21): 1558.

https://doi.org/10.1182/blood.V118.21.1558.1558

Published: 2011

Journal Articles

Use of Cytarabine for Mantle Cell Lymphoma Treatment: 10 Years of Experience of a French Haematology Department

Marie-Pierre Gourin, Julie Abraham, Franck Trimoreau, Barbara Petit, Stephane Girault, Agnes Olivrie-Gamaury, Arnaud Jaccard, Jean Feuillard, Dominique Bordessoule

Blood (2010) 116 (21): 1755.

https://doi.org/10.1182/blood.V116.21.1755.1755

Published: 2010

Journal Articles

Long-Term Outcome of Anemic Non Del 5q Lower-Risk MDS Refractory to or Relapsing After Erythropoiesis Stimulating Agents (ESAs)

Blood (2010) 116 (21): 442.

https://doi.org/10.1182/blood.V116.21.442.442

Published: 2010

Journal Articles

Non Predictive Value of An Initial Tc-99m-MIBI Scintigraphy On the Prediction of Therapeutic Outcome in Non Hodgkin and Hodgkin Lymphoma: Preliminary Results of a Prospective Study in 81 Patients .

Marie-Pierre Gourin, Jacques Monteil, Benoit Marin, Stéphane Girault, Natalya Dmytruk, Julie Abraham, Agnes Olivrie-Gamaury, Nicolas Weinbreck, Arnaud Jaccard, Jean Feuillard, Dominique Bordessoule, MD, PhD

Blood (2009) 114 (22): 4762.

https://doi.org/10.1182/blood.V114.22.4762.4762

Published: 2009

NARROW

Prognostic Characterization of Advanced Mastocytosis Patients Treated with Midostaurin According to Diagnosis and Mutation-Adjusted Risk Score: A Nation-Wide Ceremast Study of 170 Patients

Azacitidine for Patients with Vexas Syndrome: Data from the French Vexas Registry

FLT3 Ligand Kinetic Profile Predicts Response to Treatment and Event-Free Survival (EFS) in Adults with High-Risk MDS/CMML Receiving CPX-351: A GFM Study

Therapy Related Myeloid Neoplasms Following PARP Inhibitors : Real-Life Experience

Molecular Response Analysis By High Throughput Sequencing in Higher Risk Myelodysplastic Syndrome (HR-MDS) Treated Intensively with CPX-351

Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group

A Phase II Study of the Efficacy and Tolerance of Azacytidine (AZA) in Steroid Dependent/Refractory Systemic Autoimmune and Inflammatory Disorders (SAID) Associated with MDS or CMML (GFM- AZA-SAID -trial)

CPX 351 As First Line Treatment in Higher Risk MDS. a Phase II Trial By the GFM

A Molecular-Based Response Prediction Model to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome and Severe Thrombocytopenia

Biomarkers of Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - Results of the Europe Trial By the Emsco Network

French National Retrospective Cohort of Hairy-Cell Leukemias: Risk of Second Malignancies after 10 Years of Follow-up

Results of a Phase II Study of Guadecitabine (SGI-110) in Higher Risk MDS, CMML or Low Blast Count AML Patients Refractory to or Relapsing after Azacitidine (AZA) Treatment

Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup

The Revised IPSS (IPSS-R) Predicts Response To Erythropoietic Stimulating agents (ESA) In Pts With Classical IPSS Low Or Intermediate-1 (int 1)- MDS: A Joint Retrospective Study Of The GFM, Düsseldorf Registry and Fism

Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?

FDG-PET/CT Metabolic Tumor Volume: A New Prognostic Marker in Hodgkin Lymphoma?

CD68+ Tumor-Associated Macrophages Predict Unfavorable Treatment Outcomes in Classic Hodgkin's Lymphoma in Correlation with Early FDG-PET Assessment Results

Use of Cytarabine for Mantle Cell Lymphoma Treatment: 10 Years of Experience of a French Haematology Department

Long-Term Outcome of Anemic Non Del 5q Lower-Risk MDS Refractory to or Relapsing After Erythropoiesis Stimulating Agents (ESAs)

Non Predictive Value of An Initial Tc-99m-MIBI Scintigraphy On the Prediction of Therapeutic Outcome in Non Hodgkin and Hodgkin Lymphoma: Preliminary Results of a Prospective Study in 81 Patients .

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only